As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Durvalumab with tremelimumab and chemotherapy within its marketing authorisation for treating unresectable or advanced urothelial cancer [ID3855].
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early January 2026 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-March 2026.